BMO Capital Upgrades Halozyme Therapeutics (HALO) to Outperform

January 14, 2013 7:43 AM EST
Get Alerts HALO Hot Sheet
Price: $11.50 --0%

Rating Summary:
    12 Buy, 1 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 17 | New: 13
Trade HALO Now!
Join SI Premium – FREE
BMO Capital upgraded Halozyme Therapeutics (NASDAQ: HALO) from Market Perform to Outperform with a price target of $12.00 (from $4.00).

For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

Shares of Halozyme Therapeutics closed at $7.21 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Hot Upgrades, Upgrades

Related Entities

BMO Capital

Add Your Comment